Overview

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborator:
Janssen Biotech, Inc.
Treatments:
Peficitinib
Verapamil